{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000108","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.463448+00:00","generated_at":"2026-05-17T17:36:30.963777+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025","bullets":["IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.","Net loss $10.6M in Q2 2025 vs $7.2M in Q2 2024; R&D expense decreased to $7.0M.","Cash $22.1M at June 30, 2025; secured $10M non-dilutive financing in Q2 2025.","Company expects cash to fund operations into Q1 2026, beyond Phase 2 final analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000108","json":"https://secwatch.observer/filing/0001601485-25-000108.json","markdown":"https://secwatch.observer/filing/0001601485-25-000108.md","text":"https://secwatch.observer/filing/0001601485-25-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/0001601485-25-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/angn-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:36:30.963777+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}